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Abstract
Background: Refractory post-cardiotomy cardiogenic shock (PCCS) is a relatively rare phenomenon that can lead to
rapid multi-organ dysfunction syndrome and is almost invariably fatal without advanced mechanical circulatory
support (AMCS), namely extra-corporeal membrane oxygenation (ECMO) or ventricular assist devices (VAD). In this
multicentre observational study we retrospectively analyzed the outcomes of salvage venoarterial ECMO (VA ECMO)
and VAD for refractory PCCS in the 3 adult cardiothoracic surgery centres in Scotland over a 20-year period.
Methods: The data was obtained through the Edinburgh, Glasgow and Aberdeen cardiac surgery databases. Our
inclusion criteria included any adult patient from April 1995 to April 2015 who had received salvage VA ECMO or VAD
for PCCS refractory to intra-aortic balloon pump (IABP) and maximal inotropic support following adult cardiac surgery.
Results: A total of 27 patients met the inclusion criteria. Age range was 34–83 years (median 51 years). There was a
large male predominance (n = 23, 85 %). Overall 23 patients (85 %) received VA ECMO of which 14 (61 %) had central
ECMO and 9 (39 %) had peripheral ECMO. Four patients (15 %) were treated with short-term VAD (BiVAD = 1, RVAD = 1
and LVAD = 2). The most common procedure-related complication was major haemorrhage (n = 10). Renal failure
requiring renal replacement therapy (n = 7), fatal stroke (n = 5), septic shock (n = 2), and a pseudo-aneurysm at the
femoral artery cannulation site (n = 1) were also observed. Overall survival to hospital discharge was 40.7 %. All
survivors were NYHA class I-II at 12 months’ follow-up.
Conclusion: AMCS for refractory PCCS carries a survival benefit and achieves acceptable functional recovery despite a
significant complication rate.
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Background
Cardiogenic shock following cardiac surgery can affect as
many as 2–6 % of patients undergoing routine surgical
coronary revascularization or valve surgery [1–4]. Al-
though the majority of these patients respond to inotropic
support and/or intra-aortic balloon pump counter pulsa-
tion (IABP) support, 0.5–1.5 % of patients demonstrate a
rapid and progressive decline in their haemodynamic
parameters in the immediate aftermath of cardiopulmo-
nary bypass [5]. The occurrence of post-cardiotomy
cardiogenic shock (PCCS) can be unpredictable and
can occur in patients with normal preoperative myocar-
dial function as well as those with pre-existing impaired
function [6]. Refractory PCCS leads to vital organ hypo-
perfusion and is almost universally fatal [4, 7–9] with-
out the use of advanced mechanical circulatory support
(AMCS) devices such as extracorporeal membrane oxy-
genation (ECMO) or ventricular assist devices (VAD).
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In our previous study we looked at the outcomes of
AMCS utilization at the Edinburgh heart center’s
cardiothoracic surgery department (a non-transplant,
intermediate-sized, adult cardiothoracic surgery centre)
in Scotland [10]. This current multicentre observational
study aims to consolidate our previous findings and
looks at the 20-year outcomes of AMCS utilization to
salvage refractory PCCS patients in all the 3 cardiothor-
acic surgery centres in Scotland.
Methods
Scottish adult cardiothoracic surgical services are pro-
vided by three regional centres covering a population of
5.2 million individuals [11]. The relevant data was
collected from the databases of the Royal Infirmary of
Edinburgh (surgical case load ≈ 900/year), the Golden
Jubilee National Hospital in Glasgow (surgical case
load ≈ 1300/year), and the Aberdeen Royal Infirmary
(surgical case load ≈ 500/year). Our inclusion criteria
included any adult patient from April 1995 to April
2015 who had received salvage VA ECMO or VAD for
PCCS refractory to IABP and inotropic support follow-
ing adult cardiac surgery. We acquired information re-
garding the patients’ 12 month follow-up status by
accessing the cardiology follow-up clinic letters on the
TrakCareR system in Edinburgh, the AMCS database
in Glasgow, and through making direct enquiries with
the surgeons involved in the long-term outcomes of
the patients in Aberdeen via email and telephone
communications.
The AMCS devices utilised at the Royal Infirmary of
Edinburgh over the defined study period were Levitro-
nixR CentriMag II for ECMO and Medtronic Bio-
MedicusR 560 for short-term VAD support. Over the
same time period, the AMCS devices used at the Golden
Jubilee National Hospital in Glasgow and the Aberdeen
Royal Infirmary cardiac surgical units was the CentriMag
device for both VA ECMO and short-term VAD support.
Results
A total of 28 patients met the inclusion criteria with
one patient excluded due to lack of recorded informa-
tion in the TrakCareR database regarding the type of
AMCS support used, any potential complications and
the short and the long-term outcomes of this individ-
ual. Overall, 16 patients from the Royal Infirmary of
Edinburgh met the inclusion criteria, 8 patients from
the Golden Jubilee National Hospital in Glasgow and 3
patients from Aberdeen Royal Infirmary cardiothoracic
surgery unit. The reason why more cases belonged to
Edinburgh rather than Glasgow, despite the latter being
a larger unit, was because AMCS was rarely used to sal-
vage refractory PCCS patients in the west of Scotland
prior to 2007 (the year of the merger between Glasgow
Royal Infirmary and the Glasgow Western Infirmary
forming the Golden Jubilee National Hospital).
Of the total 27 patients from the 3 centres, the age
range was 34–83 years (median 59 years). There was a
large male predominance of 23 (85 %). Four patients
(15 %) had undergone re-operative cardiac surgery. One
patient (3.7 %) had undergone AMCS following the repair
of a traumatic ascending aortic transection after a road
traffic accident. Overall, 23 patients (85 %) had received a
single run of VA ECMO of which 14 (61 %) had re-
ceived central ECMO and 9 (39 %) had received periph-
eral ECMO. Four patients (15 %) had short-term VADs
(1 BiVAD, 1 RVAD and 2 LVAD). The mean duration
of AMCS was approximately 5.43 days (Range < 1 day–
33 days). The most common procedure-related compli-
cation was major haemorrhage (37 %). Renal failure re-
quiring renal replacement therapy (26 %), stroke (19 %)
and peripheral limb ischaemia (15 %, Fig. 1) were also
recorded. Logistic EuroSCORE ranged from 2.08 to
73.26. More detailed patient baseline characteristics are
tabulated in Table 1.
The most common cause of death (COD) was refrac-
tory biventricular failure that failed to recover suffi-
ciently to allow weaning from AMCS (22.2 %, Fig. 2).
In these patients care was withdrawn. One patient died
due to a combination of biventricular failure and haem-
orrhagic shock and another patient died from a com-
bination of biventricular failure and septic shock whilst
on VA ECMO. The survival rate to hospital discharge
was 40.7 % (Fig. 3). The follow-up data showed that the
survivors were all NYHA class I-II functional status at
12 months.
Statistical analysis
Statistical analysis was performed using the Fisher’s
exact and Pearson’s chi2 tests. Univariate analysis was
performed. Table 2 demonstrates the baseline statistics
data and the analytical methods used in this study.
Discussion
Our study demonstrates that AMCS used for the treat-
ment of refractory PCCS can lead to good outcomes for
a significant number of patients, with 40.7 % surviving
to hospital discharge and all surviving patients were
graded as either NYHA class I or II at 12 months’ post-
discharge. Without AMCS, it is likely that the vast ma-
jority of these patients would have died. Ours is also the
first multi-centre study of its kind to emerge from the
UK and one of the few studies to examine functional
outcomes post AMCS utilisation for refractory PCCS.
Recent evidence has demonstrated that modern,
continuous-flow AMCS devices, such as the CentriMagR
that was used in our centres, can lead to improved sur-
vival in patients with PCCS [12–14]. In the largest
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cohort, Hernandez et al. [3] collated data from 5735 pa-
tients who underwent salvage VAD for refractory PCCS.
They reported a 54.1 % survival rate to hospital dis-
charge and concluded that VAD is a valuable, life-saving
therapeutic manoeuvre. By comparison, the survival rate
in our study was lower but firm conclusions are difficult
given the low number of patients in our cohort. How-
ever, other smaller studies (relative to the Hernandez
study) [5, 15–18] all using either ECMO or VAD for
refractory PCCS, reported less impressive survival to
hospital discharge rates of 24.8 %–37 % and a 5 year sur-
vival of 13.7 %–16.9 %. Unfortunately, we do not have
long-term survival data as many of the survivors were
ultimately discharged from the outpatient clinics when
no further medical or surgical interventions were required,
hence longer term follow up data post out-patient clinic
discharge had not been recorded in the database.
We identified advanced age to be a factor leading to
an adverse outcome, although again, owing to our
smaller numbers, this did not reach statistical signifi-
cance. Most (64 %) of the survivors were under 60 years
of age. Furthermore, the emergent nature of surgery and
pre-existing, preoperative severe left ventricular impair-
ment were also identified as probable factors leading to
an adverse outcome.
Evidence suggests that early device implantation [6] and
appropriate patient selection through a multidisciplinary
team approach is paramount to an optimal outcome [10].
There are no national or local protocols for identifying
suitable patients for AMCS with refractory PCCS in
Scotland: instead, decisions are based on a case-by-case
assessment involving a multidisciplinary team (cardiac
surgeon, department head, anaesthetist, and perfusionist)
in each of the three hospital sites. We continue to believe
that this is the best approach to patient selection rather
than a standardised algorithmic approach because it en-
sures an ethically appropriate decision for the patient
whilst optimising the cost-benefit equation. The decision
regarding when to initiate AMCS support was made for
most patients whilst in theatre in those whom weaning
from CPB was not possible, although a few were com-
menced AMCS whilst in ICU. The time to AMCS and
how this correlates to survival is an important variable
that regrettably was not consistently recorded in our pa-
tient cohort.
AMCS devices are expensive [9, 19, 20] and this,
coupled with a potentially prolonged length of stay in
ICU, means that cost is an important factor in the
decision-making process, particularly within the UK
NHS. Indeed, decision-makers have opted to centralise
AMCS funding to a restricted number of the larger car-
diothoracic centres [21], invariably depriving other
units of this potentially life-saving resource. Under-
standably, this has led to expressions of consternation
[21]. In our cohort, the longest duration on AMCS was
33 days (patient 7). This patient was successfully
weaned from VA ECMO but died whilst in critical care
from a stroke, which may have been a complication
from AMCS employment.
The NYHA functional outcomes for our patients were
also very positive. Unfortunately, many previous AMCS
studies for refractory PCCS do not report such findings,
although we did identify two studies, each with similar
outcomes to ours. Ko et al. [17] detailed a cohort of 76
patients undergoing ECMO support for refractory PCCS.
They reported that all survivors were of NYHA classes
I or II at 32 +/− 22 month follow-up. Pennington et al.
[15] reported on refractory PCCS support with VAD
and found that all survivors were “leading active lives”.
In 72.7 % of their survivors, ejection fraction had nor-
malized on follow-up echocardiography.
Clearly, given that we only identified 27 patients
undergoing AMCS over a 20-year period, and despite
our pooled hospital case volume, we acknowledge that
Fig. 1 Bar chart illustrating the number and nature of complications within cohort
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Table 1 Patient baseline characteristics
Age & Gender Date of
surgery
Original operation Duration and Mode of AMCS AMCS Complication/s Outcome
Patient 1 76 year old male 2012 Re-do sternotomy and AVR Salvage peripheral VA ECMO due to postoperative
pulmonary haemorrhage and cardiogenic shock
Femoral artery cannulation site
pseudoaneurysm
Alive
NYHA I (No breathlessness
of exertion, back to work)Major haemorrhage from
cannulation site
Patient 2 40 year old male 2014 Re-do, Re-do sternotomy for type A
aortic dissection: Bentall procedure
Salvage RVAD due to VF arrest and severe LVSD
after weaning from CPB
Major haemorrhage and re-
exploration in the operating
theatre
Alive
NYHA II (Breathless on
exertion)
Patient 3 82 year old male 2006 MV Repair and CABG 3 Days Could not be weaned from
ECMO with severe biVent failure
and
Died in CTICU
VA ECMO as unable to wean from CPB COD: BiVent failure
Patient 4 72 year old Female 2011 AVR 9 Days Septic shock Died in CTICU
VA ECMO as unable to come off CPB Limb ischaemia COD: Septic shock
Patient 5 71 year old male 2011 CABG and AVR 2 Days ECMO cannulation site bleeding
and haematoma explored
Died in CTICU
Peripheral VA ECMO as unable to come off CPB COD: Shock (unknown
cause)Renal failure a
Patient 6 83 year old female 2012 MVR and CABG <1 Day None Died in CTICU
Peripheral VA ECMO as unable to wean from CPB COD: BiVent failure
Patient 7 70 year old male 2013 Re-do sternotomy and AVR 33 Days Major CVA Died in HDU




Patient 8 72 year old male 2013 Re-do sternotomy and AVR <1 Day ECMO cannulation femoral artery
dissection
Died in CTICU
VA ECMO after iatrogenic aortic dissection leading





Patient 9 51 year old male 2013 Re-suspension of Aortic valve and
repair of type A aortic dissection
1 Day Major cannulation site
haemorrhage
Died in CTICU
Peripheral VA ECMO for cardiogenic shock COD: Haemorrahgic shock
and BiVent failure
Patient 10 34 year old female 2014 IVC Leiomyosarcoma resection 3 Days None Died in CTICU
VA ECMO for postoperative cardiogenic shock for
intraoperative MI
COD: BiVent failure from
acute MI
Patient 11 65 year old male 2013 CABG 2 Days Renal failurea Died in CTICU











Table 1 Patient baseline characteristics (Continued)
Patient 12 71 year old male 2015 CABG 3 Days Major haemorrhag e: Re-opening
for bleeding x4
Died in CTICU
VA ECMO as unable to wean from CPB COD: biventricular failure
and septic shocklimb ischaemia
Patient 13 49 year old male 1997 CABG VA ECMO as unable to wean from CPB Note recorded Alive
(Died 2004)
NYHA II
Patient 14 69 year old male 2004 MVR and CABG for mitral valve IE VA ECMO as unable to wean from CPB CVA and seizures Alive
Renal failure a NYHA II
Patient 15 41 year old female 2005 Aortic transection and diaphragm
rupture
VA ECMO Not recorded Alive
NYHA I
Patient 16 59 year old male 2006 Type A aortic dissection 2 Days Not recorded Died
Peripheral VA ECMO as unable to wean from CPB COD: Bivent failure
Patient 17 21 year old male 2014 AVR 3 days ECMO cannulation site bleeding-
required re-exploration
Alive
Peripheral VA ECMO NYHA I
Cardiac tamponade
Patient 18 51 year old male 2014 AVR 6 days CVA and Seizures Died in ICU
Peripheral VA ECMO limb ischaemia COD: status epilepticus
Patient 19 46 year old male 2014 CABG 2 days Major haemorrahage Died in ICU
Peripheral VA ECMO converted to central VA ECMO




Patient 20 54 year old male 2015 CABG and AVR 3 days SVT/VT Alive
VA ECMO for cardiogenic shock Major intra-abdominal haemor-
rhage requiring laparotomy
NYHA II (Neuropathic leg
pain)
Limb ischaemia
Patient 21 56 year old male 2015 AVR 3 days CVA (occipital infarcts) Alive
Peripheral VA ECMO for cardiogenic shock NYHA I (Visual difficulties)
Patient 22 64 year old male 2015 AVR 1 day Vasoplegia Died
VA ECMO MODS COD: AV dissociation
Patient 23 52 year old male 2015 CABG 1 day MODS Died
VA ECMO COD: MODS
Patient 24 64 year old male 2015 AVR 7 days None Alive










Table 1 Patient baseline characteristics (Continued)
Patient 25 50 year old male 2014 AVR 23 days Renal failurea Alive
BiVAD NYHA IHaemothorax/mediastinal
collection requiring re-operation
Patient 26 54 year old male 2015 Bentall’s procedure and CABG
surgery
2 days Hepatic failure COD: MODS
LVAD acute LV failure Renal failure pleasea
Patient 27 61 year old male 2003 CABG 11 days Respiratory failure Alive
LVAD for acute LV failure Renal failurea NYHA II
Abbreviations: ACS Acute coronary syndrome, AF atrial fibrillation, AMCS Advanced mechanical circulatory support, AVR Aortic valve replacement, CABG Coronary artery bypass grafting surgery, CPB Cardiopulmonary
bypass, COD cause of death, BiVent failure BiVentricular failure, MVR Mitral valve replacement, IE Infective endocarditis, CVA Cerebrovascular accident, IVC Inferior vena-cava, NYHA New York Heart Association, CTICU car-
diothoracic Intensive care unit, HDU High dependency unit, Implantable cardioverter defibrillator, MI Myocardial infarction, LVSD Left ventricular systolic dysfunction, TVD triple vessel coronary artery disease, LV left ven-
tricular, MR Mitral regurgitation, PVD Peripheral vascular disease, MODS Multi-organ dysfunction syndrome, VF Ventricular fibrillation, VAD Ventricular assist device, VA Veno-Arterial










the Scottish approach to institution of AMCS for re-
fractory PCCS has been relatively conservative. This
can partly be explained by the fact that salvage AMCS
was not employed in the west of Scotland until 2007.
Also, our general approach to institution of AMCS dic-
tates that such modalities are instituted only if there is
a reversible cause of the cardiogenic shock, which is
reflected by our reasonable survival rate. Other possible
reasons for underutilization may include: scarcity of
resources, prohibitive costs, and lack of consistent evi-
dence for the benefit of AMCS.
The decision to institute AMCS must also be bal-
anced with due consideration of the associated risks of
this invasive modality, many of which are potentially
life-threatening. Common device-related complica-
tions include: haemorrhage, thrombus formation and
embolization, stroke, device-related infection, limb is-
chaemia, and multi-organ dysfunction syndrome/failure
Fig. 2 Bar chart illustrating the number and causes of death within cohort. AV: atrioventricular
Fig. 3 Kaplan-Meier curve of survival, x-axis represents follow-up (FU) in days and y-axis represents cumulative survival (Cum survival)
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[1, 2, 15, 17, 22, 23]. In our cohort, the most common
procedure-related complication was major haemorrhage.
Renal failure requiring renal replacement therapy, stroke,
and peripheral limb ischaemia also occurred with compar-
able rates to previous studies.
Given the scarcity of donor hearts in the UK, research
continues to focus on implantable AMCS devices as a
bridge to recovery, bridge to transplant, or as destination
therapy [19]. However, none of our patients were trans-
planted during the study period and none had implant-
able long-term VADs.
Finally, this study is limited by the small number of
subjects (as previously discussed) and its retrospective
nature. It nevertheless reaffirms the findings of our
Table 2 Demonstrates variables used for statistical analysis. Fisher’s exact test and Pearson’s chi test (Log. EuroSCORE) were utilized
for statistical analysis
Factors attributed to mortality and statistical analysis
Characteristics analyzed Alive Dead Odds ratio (95 % Conf. interval) p-value
Age (years)
0–65 8 10 2.8 (0.362853–33.74714) 0.24
> 65 2 7
Gender
Male 9 14 1.928571 (0.1270413–112.3145) 0.5
Female 1 3
Type of center
Transplant 4 5 0.625 (0.0921389–4.488993) 0.44
Non-transplant 6 12
Prev. cardiac surgery
Re-do surgery 2 2 0.5333333 (0.0335265–8.873345) 0.48
First time surgery 8 15
Surgical complexity
Isolated surgery 6 10 1.05 (0.1662785–7.107629) 0.64
Complex surgery 4 7
Type of Support
VAD 3 1 0.1458333 (0.0026189–2.352801 0.13
ECMO 7 16
Duration of Support
0–7 days 8 15 0.5333333 (0.0335265 8.873345) 0.47
> 7 days 2 2
Support complications
Major haemorrhage 5 5 0.4166667 (0.0620347–2.804408) 0.25
No major haemorrhage 5 12
Major CVA 1 4 2.769231 (0.2140667–151.2664) 0.37
No major CVA 9 13
Renal failure 3 4 0.7179487 (0.0910803–6.420841) 0.52
No renal failure 7 13
Log. EuroSCORE
0–10 1 3 0.36 (Pearson’s chi2 test)
10–20 1 6
> 20 4 3
Score not available 4 5
Table information: Prev.cardiac surgery denotes whether the patient had had previous cardiac surgery through median sternotomy (i.e. redo surgery). Isolated
surgery refers to whether the operation was isolated coronary artery bypass grafting surgery (CABG) or single valve surgery. Complex cardiac surgery refers to
combined valve, CABG and/or aortic surgery. Type of center denotes whether the operating hospital in which the operation was performed was a cardiopulmonary
transplant center. Log. EuroSCORE refers to logistic EuroSCORE
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previous study, which reported a good survival rate and
acceptable quality of life for patients who received
AMCS for refractory PCCS and survived to hospital
discharge.
Conclusions
AMCS devices can be used to salvage a significant propor-
tion of patients with refractory PCCS who would otherwise
not survive. These patients are also likely to enjoy a rea-
sonable quality of life. However, ACMS devices are associ-
ated with high rates of severe, systemic and device-related
complications as well as being costly. Multidisciplinary
teams experienced with patient selection and decision-
making are imperative to help ensure appropriate use of
AMCS and the best patient outcomes.
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CTICU: Cardiothoracic Intensive care unit; HDU: High dependency unit;
ICD: Implantable cardioverter defibrillator; MI: Myocardial infarction;
LVSD: Left ventricular systolic dysfunction; TVD: triple vessel coronary artery
disease; LV: left ventricular; MR: Mitral regurgitation; PVD: Peripheral vascular
disease; MODS: Multi-organ dysfunction syndrome; VF: Ventricular fibrillation;
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